Abstract
Background
After improved long-term survival in young women with lymphoma and leukemia undergoing chemotherapy, preservation of future fertility has been the focus of recent interest. The investigational endeavors of ovarian cryopreservation await the clinical experience of in vitro maturation of thawed primordial follicles, their in vitro fertilization, and embryo transfer. Although promising, this experience is not yet available. Moreover, the risk of possible reimplantation of malignant stem cells with the thawed cryoperserved ovary has been raised after experimental animal observations. Therefore, until these innovative endeavors prove successful, and in parallel with them, we attempted to minimize the gonadotoxic effect of chemotherapy by the cotreatment with a gonadotropin-releasing hormone (GnRH) agonistic analogue to induce a temporary prepubertal milieu. Whereas inhibin-B concentrations in serum may reflect the ovarian granulosa cell compartment, inhibin-A reflects luteal function. Immunoreactive inhibin-A and -B in these patients before, during, and after gonadotoxic chemotherapy were measured.
Methods
A prospective clinical protocol was undertaken in 44 women with lymphoma, aged 15–40 years, ten with leukemia and eight undergoing chemotherapeutic treatments for nonmalignant diseases such as systemic lupus erythematosus or other autoimmune diseases. A monthly injection of depot D-TRP6-GnRH-a was administered from before the start of chemotherapy until its conclusion, up to a maximum of 6 months. A hormonal profile was taken before starting the GnRH-a/chemotherapy cotreatment, and monthly thereafter until the women resumed spontaneous ovulation. This group was compared with a control group of 55 women who had been treated with similar chemotherapy. Inhibin-A and -B immunoactivity was measured.
Results
Whereas all but one (40-year-old) of the surviving patients with GnRH-a/chemotherapy cotreatment group resumed spontaneous ovulation and menses within 6 months, fewer than half of the patients in the control group (chemotherapy without GnRH-A cotreatment) resumed ovarian function and regular cyclic activity (P < .05). The remaining 60% experienced premature ovarian failure (POF). Temporary increased follicle-stimulating homrone (FSH) concentrations were experienced by almost a third of the patients resuming cyclic ovarian function, suggesting a reversible ovarian damage in a larger proportion of women than those experiencing POF. Inhibin-A and -B decreased during GnRH-a/chemotherapy cotreatment but increased to normal levels in patients who resumed regular ovarian cyclicity and/or spontaneously conceived, compared with low levels in those who developed POF.
Conclusions
If these preliminary data are consistent in a larger group of patients, inhibin-A or -B concentrations may serve as prognostic factors to predict the resumption of ovarian function, in addition to the levels of FSH, luteinizing hormone, and estradiol. GnRH-a cotreatment should be considered for every woman of reproductive age who receives chemotherapy, in addition to assisted reproductive technology and the investigational attempts of ovarian cryopreservation for future in vitro maturation.
Article PDF
Avoid common mistakes on your manuscript.
References
Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997;29:199–206.
Gosden RG, Rutherford AJ, Norfolk DR. Debate: Ovarian banking for cancer patients. Transmission of malignant cells in ovarian grafts. Hum Reprod 1997;12:403.
Shaw J, Trounson A. Oncological implications in the replacement of ovarian tissue. Hum Reprod 1997;12:403–5.
Glaser SL. Reproductive factors in Hodgkin disease in women: A review. Am J Epidemiol 1994;139:237–46.
Ataya K, Moghissi K. Chemotherapy induced premature ovarian failure: Medications and prevention. Steroids 1989;54:607–26.
Magrath I. Limiting therapy for limited childhood non-Hodgkin’s lymphoma. N Engl J Med 1997;337:1304–6.
De Vita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin disease. Ann Intern Med 1970;73:881–6.
DeVita VT, Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 1980;92:587–95.
Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 1999;6:229–39.
Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin’s disease. I. Hormonal function. JAMA 1979;242:1877–81.
Kreuser ED, Xirus N, Hetzel WD, Himpel A. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapv of Hodgkin’s disease. J Cancer Res Clin Oncol 1987;113:260–6.
Rivkees SA, Crawford JD. The relationship of gonadal damage. JAMA 1988;259:2123–5.
Shafet SM, Beardwell CG, Morris PH, Pearson D, Orrell DH. Ovarian failure following abdominal irradiation in childhood. Br J Cancer 1976;33:655–8.
Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. Prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;45:3651–6.
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–29.
Muller U, Stahel RA. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin lymphoma. Ann Oncol 1993;4:399–402.
Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anaemia or leukaemia. J Clin Oncol 1988;6:813–7.
Trounson AO, Bongso A. Fertilization and development in humans. Curr Topics Dev Biol 1996;32:59–101.
Vincent C, Johnson MH. Cooling, cryoprotectants and the cytoskeleton of the mammalian oocyte. Oxford Rev Reprod Biol 1992;14:72–100.
Barnes FL, Kausche A, Tiglias J, Wood C, Wilton L, Tronnson A. Production of embryos from in-vitro matured primary human oocytes. Fertil Steril 1996;65:1151–6.
Apperly JF, Reddy N. Mechanism and management of gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev 1995;9:93–116.
Theriault RL, Sellin RV. Estrogen-replacement therapy in younger women with breast cancer. Monogr Natl Cancer Inst 1994;16:149–52.
Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 occurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1–15, 71–85.
Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977;i:l 174–6.
Gosden RG. Transplantation of ovaries and testes. In: Edwards RG, ed. Fetal tissue transplants in medicine. Cambridge: Cambridge University Press, 1992:253–79.
Shaw JM, Bowels J, Koopman P. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to the graft recipient. Hum Reprod 1996;11:1668–73.
Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620–6.
Blumenfeld Z, Ritter M, Shariki K, Haim N. Inhibin-A concentrations in sera of young women during and following chemotherapy for lymphoma: Correlation with ovarian toxicity. Presented at the 44th Annual Meeting of the Society for Gynecologic Investigation, San Diego, CA, March 20–22, 1997. J Soc Gyn Investig (Suppl.). Am J Reprod Immunol 1998;39:33–40.
Groome NP, O’Brien M. Two-site immunoassays for inhibin and its subunits: Further applications of synthetic peptide approach. J Immunol Methods 1993;165:167–76.
Ortin TT, Shoshlak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: The Stanford experience. Int J Radiol Oncol Biol Phys 1990;19:873–80.
Ataya K, Rao LV, Laurence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 1995;52:365–72.
Krause W, Pfluger KH. Treatment with the gonadotropin-releasing hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia 1989;21:265–70.
Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987;317:1315–21.
Jarrell JF, McMahon A, Barr RD, Young Lai EV. The agonist (d-leu-6, des-gly-10)-LHRH-ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation. Reprod Toxicol 1991;5:385–8.
Sobrinho LG, Levine RA, DeConti RC. Amenorrhea in patients with Hodgkin’s disease treated with antineoplastic agents. Am J Obstet Gynecol 1971;109:135–9.
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878–86.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000;342:1887–92.
Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:1–5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from the Technion-Israel Institute of Technology, Ministry of Health, and the A. Tufeld Cancer Research Fund.
Presented in part at the 46th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, GA, March 10–13, 1999.
A review of this subject was previously published in J Soc Gynecol Investig 1999;6:229–39.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Blumenfeld, Z. Ovarian Rescue/Protection From Chemotherapeutic Agents. Reprod. Sci. 8 (Suppl 1), S60–S64 (2001). https://doi.org/10.1177/1071557601008001S19
Published:
Issue Date:
DOI: https://doi.org/10.1177/1071557601008001S19